The Claim
In human colorectal cancer tissues with low glucose availability, tumor cells upregulate the GLUT5 transporter to metabolize fructose as an alternative energy source, enabling sustained proliferation and resistance to chemotherapy through enhanced glycolytic and tricarboxylic acid cycle flux.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In human colorectal tumors with low glucose, tumor cells increase GLUT5 transporter activity to use fructose for energy, which supports continued growth and reduces the effectiveness of chemotherapy by boosting glycolysis and tricarboxylic acid cycle activity.
See the scientific wording
In human colorectal cancer tissues with low glucose availability, tumor cells upregulate the GLUT5 transporter to metabolize fructose as an alternative energy source, enabling sustained proliferation and resistance to chemotherapy through enhanced glycolytic and tricarboxylic acid cycle flux.
When glucose is scarce in colorectal tumors, cancer cells open more fructose gates called GLUT5 to pull fructose inside. Fructose binds to a protein called KHK, which stops that protein from being broken down. This trapped KHK forces fructose into energy-producing pathways that make fuel and building blocks for the tumor, allowing it to keep growing and survive chemotherapy.
What the research says
1 studyWhen colorectal cancer cells don't have enough glucose, they use fructose instead by turning on a special gate called GLUT5 to let fructose in. This helps them keep growing and survive chemotherapy. The study proved this happens in real human tumors.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.